Prednisolone (30-60 mg/day) for diseases other than AD decreases amyloid beta-peptides in CSF.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 12011295.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The effect of corticosteroid on the concentration of amyloid beta-peptide (Abeta) in human CSF obtained from 16 patients without dementia treated with prednisolone (> or =30 mg daily) was studied. The concentrations of Abetax-40 and Abetax-42 in CSF decreased after treatment was started (p < 0.002). A moderate- or high-dose regimen of prednisolone decreases Abeta production or increases Abeta degradation in the human brain and deserves further study in AD.
Medical subject headings
- Amyloid beta-Peptides
- Cranial Nerve Diseases
- Multiple Sclerosis
- Peptide Fragments
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Prednisolone